Neoparin Forte (Enoxaparin Sodium)

Neoparin Forte, a low molecular weight heparin, is used in several thromboembolic disease pathways.

• Deep vein thrombosis (DVT): prevention of clot formation in at‑risk surgical or medical patients.
• Pulmonary embolism (PE): treatment of acute embolic events to restore pulmonary circulation.
• Post‑operative prophylaxis: reduction of venous thromboembolism risk after orthopedic and general surgery.
• Acute coronary syndrome (ACS): adjunct therapy to inhibit further clot propagation in unstable angina or non‑ST elevation myocardial infarction.
• Cardiac catheterisation: prevention of procedural thrombosis during invasive coronary procedures.

• Enoxaparin sodium binds to antithrombin III, inducing a conformational change that markedly accelerates inhibition of activated factor Xa and, to a lesser extent, thrombin (factor IIa). By reducing generation of fibrin and platelet activation, it interrupts the coagulation cascade, thereby preventing clot extension and formation in the venous and arterial systems. The preferential inhibition of factor Xa provides a more predictable anticoagulant response compared with unfractionated heparin.

Enoxaparin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Injection site bruising or erythema
• Minor bleeding (e.g., gum or nosebleeds)
• Nausea or mild gastrointestinal discomfort
• Headache

Serious or Rare Side Effects

• Major hemorrhage (intracranial or gastrointestinal)
• Heparin‑induced thrombocytopenia (HIT)
• Allergic reactions including anaphylaxis
• Spinal or epidural hematoma following neuraxial procedures

When using Neoparin Forte, clinicians should observe several safety considerations.

• Renal impairment: dose adjustment may be required in patients with reduced creatinine clearance.
• Pregnancy: category B; benefits must outweigh potential risks.
• Surgery or invasive procedures: discontinue before neuraxial anesthesia to lower bleeding risk.
• Concomitant anticoagulants or antiplatelet agents: monitor closely for additive bleeding.
• Platelet monitoring: check platelet counts regularly to detect HIT.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Enoxaparin can interact with other medicines, altering its anticoagulant effect or increasing bleeding risk.

Major Interactions (Avoid)

• Warfarin: combined use markedly raises bleeding risk.
• Direct thrombin inhibitors (e.g., dabigatran): additive anticoagulation may cause severe hemorrhage.
• Other heparins or LMWHs: concurrent therapy can lead to excessive anticoagulation.
• Fibrinolytic agents (e.g., alteplase): heightened risk of major bleeding.

Moderate Interactions (Monitor Closely)

• Antiplatelet drugs (e.g., clopidogrel, aspirin): increase minor bleeding tendencies.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate gastrointestinal bleeding.
• Selective serotonin reuptake inhibitors (SSRIs): potential for increased bleeding risk.